SignalXSignalX

RCUS Arcus Biosciences, Inc.

Q3 2025 10-Q
Filed: Oct 28, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Arcus Biosciences, Inc. Overview

Arcus Biosciences, Inc. (RCUS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 28, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New risk: Paused etrumadenant development in third-line metastatic colorectal cancer to focus resources on late-stage clinical portfolio and research programs
  • • Most updated risk: Cash $841M through pivotal readouts based on prioritization; risk of needing more capital could restrict R&D or cause dilution
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$6M

▼ -87.5% YoY▼ -25.0% QoQ

Net Income

-$135M

▼ -46.7% YoY

Operating Margin

-2366.7%

▼ -214792bp YoY▼ -226667bp QoQ

Net Margin

-2250.0%

▼ -205833bp YoY▼ -225000bp QoQ

ROE

-31.0%

Total Assets

$974M

EPS (Diluted)

$-1.30

▼ -27.5% YoY▼ -2700.0% QoQ

Operating Cash Flow

-$97M

▼ -473.1% YoY▲ +27.1% QoQ

Source: XBRL data from Arcus Biosciences, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Arcus Biosciences, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.